cipla

Jefferies raised Bharti Airtel's target price to Rs 2,350 on strong Q4FY26 performance, while JP Morgan upgraded cipla to overweight citing improved earnings visibility and attractive valuations. Morgan Stanley maintained an underweight rating on Dixon Technologies due to revenue and EBITDA misses, and HDFC Securities upgraded Hyundai Motor India to add, noting management's renewed focus on domestic growth and exports.

Indian equity benchmarks Sensex and Nifty closed lower on Tuesday after a late sell-off in heavyweight stocks like HDFC Bank and Reliance Industries erased early gains. Concerns over the rupee hitting a fresh record low and elevated crude oil prices also weighed on investor sentiment, though IT stocks provided some support.

Khilafat House, once a hub for nationalist leaders and the Khilafat movement, is set to transform into a modern skyscraper. This historic Byculla building, gifted by the Sobani brothers, will house educational institutions, a hospital, and conference facilities, ensuring continued revenue for the Khilafat Committee trust's charitable activities.

The Indian stock market saw mixed movements today, with the BSE and NSE experiencing gains and losses across various sectors. Trent and SBI emerged as top gainers on both exchanges, while companies like Titan and Axis Bank faced declines. Technology and banking stocks showed a general downward trend.

Analysts have adjusted targets for several companies, with UBS neutral on cipla citing supply headwinds despite a healthy pipeline. Motilal Oswal initiated coverage on Bajaj Finserv with a neutral rating, highlighting its strong customer base and predictable earnings. Jefferies is bullish on LG India, anticipating price hikes due to rising costs and a weak rupee.

Pharmaceuticals firm cipla Ltd on Friday reported a 44.9 per cent rise in consolidated profit after tax at Rs 1,155.37 crore in the second quarter ended September 2023. The company had posted a consolidated profit after tax of Rs 797.41 crore in the July-September quarter last fiscal, cipla Ltd said in a regulatory filing. Consolidated total revenue from the sale of products in the quarter under review stood at Rs 6,589.22 crore, up 14.41 per cent, as against Rs 5,759.28 crore in the year-ago period.

Drug major cipla posted 10.28 per cent rise in consolidated net profit at Rs 485.35 crore for the first quarter ended June 30, 2013.

cipla, India's second-largest drug firm, has agreed to acquire South African drugmaker cipla Medpro, taking an important step towards consolidating its international business that now makes up more than half its quarterly revenues.

Mumbai, Sep 28 () Pharma firm cipla today said that environment for the domestic pharma companies remain challenging with more products coming under price control and urged the government to support the industry.

The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6-17, the Mumbai-based drug firm said in a regulatory filing on Saturday.

cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in India, Europe, and Africa. Total income from operations rose to ₹6,957 crore. The company's India market sales grew by 6% to ₹3,070 crore, while North America sales saw a 7% decline. Following the earnings announcement, cipla shares traded 3.

Drug major cipla on Tuesday said the government has approved an investment by Mauritius-based FIL Capital Investments in its subsidiary cipla Health Ltd. The investment is still subject to other conditions precedent and the transfer of company's consumer healthcare business to cipla Health Ltd.

Drug major cipla has entered into agreements to acquire US-based InvaGen Pharmaceuticals and Exelan Pharmaceuticals, owned by one of the promoters of Hetero Group, in an all cash transaction of $550 million (approx Rs 3,652 crore).

New Delhi, Aug 12 () In a major top management rejig, pharma major cipla today named Samina Vaziralli as Executive Vice-Chairman and Umang Vohra as the Managing Director and Global CEO with effect from September 1, 2016.